Nominate a development candidate for next-generation menin inhibitor program for diabetes
Delivered after the deadline (38 days after the deadline)
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 5 Feb 2025
- Due
- 30 Jun 2025
- Delivered
- 7 Aug 2025
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Nominate a development candidate for next-generation menin inhibitor program for diabetes 1H 2025”
What we found
Evidence strength A What the grades mean
Kura announced nomination of the next-generation menin inhibitor for diabetes (later named KO-7246) in its Q2 2025 results, dated August 7, 2025, after the stated mid-2025/June 30 deadline.
-
A EX-99.1 (Kura Oncology Q2 2025 Financial Results, SEC 8-K) States Kura has nominated a next-generation menin inhibitor for diabetes.
-
B Kura Oncology Reports First Quarter 2025 Financial Results Reiterates goal to nominate a development candidate in mid-2025 (pre-deadline).
-
B Kura Oncology Reports Second Quarter 2025 Financial Results Confirms nomination announcement in press release.
-
B Kura Oncology Launches Caspian Therapeutics with $50 Million Financing Confirms nominated candidate KO-7246 later advanced via Caspian subsidiary.
Checked 12 Sep 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Product other
- Indicative materiality
- Low rules
- Action
- Nominate
How this entry was checked
- Commitment recordedRecorded from the company's filing.
- First checkAn AI model read the company's later filings and recorded the outcome with a quoted passage.
- Second check: disagreesGemini (Google) re-read the evidence blind and read it as “Met”.
- Tie-breakA stronger model read the evidence and both earlier answers, without knowing which was recorded, and reads it as “no_evidence”.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Kura Oncology, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2025-KURA-000227 · Corrections policy